Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Podobne zapisy

• Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
  od: Uemura, Hirotsugu, i wsp.
  Wydane: (2019)
• Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
  od: Uemura, Hiroji, i wsp.
  Wydane: (2017)
• Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation
  od: Hosono, Makoto, i wsp.
  Wydane: (2018)
• Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
  od: Uemura, Hirotsugu, i wsp.
  Wydane: (2021)
• Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
  od: Ogawa, Kazuma, i wsp.
  Wydane: (2020)